HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing

T. Ruggiero; E. Burdino; A. Calcagno; S. Bonora; L. Boglione; G. Di Perri; V. Ghisetti

doi:10.1007/s15010-016-0937-4

HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing

T. Ruggiero, E. Burdino, A. Calcagno, S. Bonora, L. Boglione, G. Di Perri, V. Ghisetti

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Purpose: Data on the frequency of HCV naturally occurring drug-resistant variants (RAVs) at baseline in HIV/HCV coinfected patients are scarce. Methods: NS3-HCV RAVs were studied by full-population direct sequencing from plasma specimens of 345 DAA-naïve patients with HCV chronic hepatitis (159 of them with HIV/HCV-coinfection). Results: NS3 RAVs were identified in 31.5 % of patients, with a significant proportion of HIV/HCV coinfected DAA-naïve patients compared to those with HCV monoinfection (38 vs. 25 % p = 0.0104, OR 1.84; 95 % CI 1.162–2.916). Conclusions: HCV resistance genotyping test before treatment may be worth in special populations such as HIV/HCV coinfection to optimize patient treatment.

Lingua originale	Inglese
pagine (da-a)	789-792
Numero di pagine	4
Rivista	Infection
Volume	44
Numero di pubblicazione	6
DOI	https://doi.org/10.1007/s15010-016-0937-4
Stato di pubblicazione	Pubblicato - 1 dic 2016
Pubblicato esternamente	Sì

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1007/s15010-016-0937-4

Altri file e collegamenti

Link to publication in Scopus

Cita questo

@article{d658702f33ba4cfbb2cd88811d4572be,

title = "HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-na{\"i}ve patients: consideration for HCV genotyping resistance testing",

abstract = "Purpose: Data on the frequency of HCV naturally occurring drug-resistant variants (RAVs) at baseline in HIV/HCV coinfected patients are scarce. Methods: NS3-HCV RAVs were studied by full-population direct sequencing from plasma specimens of 345 DAA-na{\"i}ve patients with HCV chronic hepatitis (159 of them with HIV/HCV-coinfection). Results: NS3 RAVs were identified in 31.5 % of patients, with a significant proportion of HIV/HCV coinfected DAA-na{\"i}ve patients compared to those with HCV monoinfection (38 vs. 25 % p = 0.0104, OR 1.84; 95 % CI 1.162–2.916). Conclusions: HCV resistance genotyping test before treatment may be worth in special populations such as HIV/HCV coinfection to optimize patient treatment.",

keywords = "DAAs, HIV/HCV coinfected, Hepatitis C virus, RAVs",

author = "T. Ruggiero and E. Burdino and A. Calcagno and S. Bonora and L. Boglione and {Di Perri}, G. and V. Ghisetti",

note = "Publisher Copyright: {\textcopyright} 2016, Springer-Verlag Berlin Heidelberg.",

year = "2016",

month = dec,

day = "1",

doi = "10.1007/s15010-016-0937-4",

language = "English",

volume = "44",

pages = "789--792",

journal = "Infection",

issn = "0300-8126",

publisher = "Urban und Vogel",

number = "6",

}

TY - JOUR

T1 - HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients

T2 - consideration for HCV genotyping resistance testing

AU - Ruggiero, T.

AU - Burdino, E.

AU - Calcagno, A.

AU - Bonora, S.

AU - Boglione, L.

AU - Di Perri, G.

AU - Ghisetti, V.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Purpose: Data on the frequency of HCV naturally occurring drug-resistant variants (RAVs) at baseline in HIV/HCV coinfected patients are scarce. Methods: NS3-HCV RAVs were studied by full-population direct sequencing from plasma specimens of 345 DAA-naïve patients with HCV chronic hepatitis (159 of them with HIV/HCV-coinfection). Results: NS3 RAVs were identified in 31.5 % of patients, with a significant proportion of HIV/HCV coinfected DAA-naïve patients compared to those with HCV monoinfection (38 vs. 25 % p = 0.0104, OR 1.84; 95 % CI 1.162–2.916). Conclusions: HCV resistance genotyping test before treatment may be worth in special populations such as HIV/HCV coinfection to optimize patient treatment.

AB - Purpose: Data on the frequency of HCV naturally occurring drug-resistant variants (RAVs) at baseline in HIV/HCV coinfected patients are scarce. Methods: NS3-HCV RAVs were studied by full-population direct sequencing from plasma specimens of 345 DAA-naïve patients with HCV chronic hepatitis (159 of them with HIV/HCV-coinfection). Results: NS3 RAVs were identified in 31.5 % of patients, with a significant proportion of HIV/HCV coinfected DAA-naïve patients compared to those with HCV monoinfection (38 vs. 25 % p = 0.0104, OR 1.84; 95 % CI 1.162–2.916). Conclusions: HCV resistance genotyping test before treatment may be worth in special populations such as HIV/HCV coinfection to optimize patient treatment.

KW - DAAs

KW - HIV/HCV coinfected

KW - Hepatitis C virus

KW - RAVs

UR - http://www.scopus.com/inward/record.url?scp=84982094900&partnerID=8YFLogxK

U2 - 10.1007/s15010-016-0937-4

DO - 10.1007/s15010-016-0937-4

M3 - Article

SN - 0300-8126

VL - 44

SP - 789

EP - 792

JO - Infection

JF - Infection

IS - 6

ER -

HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo